A phase II dose-response study of NETU in patients receiving highly emetogenic chemotherapy

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222433

Enrollment

400

Registered

2014-03-25

Start date

2014-03-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy-induced nausea and vomiting

Interventions

investigational material(s) Generic name etc : NETU INN of investigational material : Netupitant Therapeutic category code : 239 Other agents affecting digestive organs Dosage and Administration for I

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are able to orally take the study drug Patients who are scheduled to receive chemotherapy including the following HEC agents Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 to 1 Patients who have provided written informed consent

Exclusion criteria

Exclusion criteria: Patients with any severe or difficult-to-control coexisting condition Patients with infection, diabetes mellitus, or other disease to whom the investigator (or subinvestigator) judges it difficult to administer steroids during the study period Patients who are unable or unwilling to cooperate in the implementation of study procedures

Design outcomes

Primary

Measure	Time frame
CR rate during the first 120 hours after the start of administration of an HEC	—

Secondary

Measure	Time frame
Efficacy Safety Pharmacokinetics	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026